Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268601 | 0.78 | — | — | |
| SCHEMBL6259613 | 0.74 | — | — | |
| SCHEMBL15158954 | 0.74 | SMPD3 (0.33) | ALOX5 | |
| SCHEMBL23769005 | 0.68 | ALOX5 (0.38) | ALOX5 | |
| SCHEMBL14948296 | 0.67 | HDAC1 (0.41) | — | |
| SCHEMBL14300085 | 0.66 | NPC1 (0.34) | — | |
| SCHEMBL29670493 | 0.64 | KDM4E (0.34) | — | |
| SCHEMBL4092525 | 0.64 | ADRA2A (0.40) | — | |
| SCHEMBL9054451 | 0.62 | APLNR (0.30) | — | |
| SCHEMBL10021906 | 0.61 | SMPD3 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126986-B2 | Hetero-bicyclic derivatives as HCV inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2015-09-08 | — | — | US | disclosed |
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | JANSSEN SCIENCES IRELAND UC (IE) | 2014-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357626-A1 | Hetero-Bicyclic Derivatives As HCV Inhibitors | HAVCR2, ZC3HAV1, SUB1 | ALOX5 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.